Stock OCERA THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Ocera Therapeutics Inc

Equities

US67552A1088

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
GL
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017
GL
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
GL
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
GL
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2
GL
Ocera Therapeutics : Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics
PR
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
GL
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017
GL
Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
GL
Ocera to Present at the 16th Annual Needham Healthcare Conference
GL
Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
GL
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
GL
Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference
GL
Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
GL
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
GL
Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
GL
Ocera to Present at the Stifel 2016 Healthcare Conference
GL
Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update
GL
Ocera Therapeutics : Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors
PU
Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Ocera Therapeutics Inc